CILcare, a CRO specializing in ear disorders, announced the appointment of Aurore Marie at the position of Global Head, R&D Operations Management. In her new role, Marie will drive support for production activities at the global level and will serve as a new member of CILcare’s Board, according to the company.
For the past six years, Marie has served as R&D project manager and senior operations manager at CILcare, responsible for directing and executing sponsor’s studies and internal R&D programs, both in Montpellier, France, and Lexington, Mass. She was notably principal Investigator on GLP ototoxicity and general toxicity studies over the last three years. Within her new position of Global Head, R&D Operations, she will manage and monitor CILcare’s French- and US-based production and “ensure maintenance of the highest level of excellence of the technology platform.”
“We are pleased to welcome Aurore in this new position and to CILcare’s board,” said Celia Belline, CEO. “Aurore is an accomplished otology scientist with a brilliant track record of operations management. Her deep experience in managing preclinical studies in France and in the US with strong knowledge in the hearing field and electrophysiology measurements will be invaluable to CILcare and its customers.”
Reporting directly to CILcare’s CEO, Marie will be working closely with CILcare’s US partner CBSET. In order to keep CILcare at the forefront of innovation, she will be in charge of keeping and developing auditory technical and surgical skills needed for next-generation medicines such as cell and gene therapies.
“I am delighted to be joining CILcare’s Board at this stage of the company’s development,” said Marie. “CILcare’s unique know-how allows it to deliver high-quality services to pharma, biotech, and medtech companies. I look forward to working with the Board to continue growing the company and delivering value for our sponsors which will benefit millions of hearing-impaired people worldwide.”
Marie holds a master’s degree in project management and innovation in biotechnology, specializing in auditory in vivo pharmacology.